Related Experiment Video
Updated: Sep 4, 2025
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
14.4K
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren1, John M Kane2, Mark Agulnik3
11Fox Chase Cancer Center.
Summary
Soft tissue sarcomas (STS) are rare cancers originating from connective tissues. These NCCN Guidelines provide expert recommendations for diagnosing and treating various STS types, emphasizing a multidisciplinary approach.
Area of Science:
- Oncology
- Pathology
Background:
- Soft tissue sarcomas (STS) are rare, heterogeneous malignancies arising from mesenchymal cells.
- STS can originate from various connective tissues, including fat, muscle, nerves, and blood vessels.
- Effective management necessitates a multidisciplinary team with specialized expertise.
Purpose of the Study:
- To present the NCCN Clinical Practice Guidelines for Soft Tissue Sarcoma.
- To provide recommendations for the diagnosis, evaluation, and treatment of STS.
- To focus on general principles for retroperitoneal/intra-abdominal STS, including treatment recommendations and supporting evidence.
Main Methods:
- Guidelines development based on expert consensus and evidence review.
- Comprehensive review of diagnostic and therapeutic strategies for STS.
- Specific focus on retroperitoneal/intra-abdominal STS within the broader guidelines.
Main Results:
- The NCCN Guidelines offer a structured approach to STS management.
- Recommendations cover diagnosis, evaluation, and treatment across diverse STS subtypes.
- Detailed guidance is provided for retroperitoneal/intra-abdominal STS.
Conclusions:
- A multidisciplinary team approach is crucial for optimal STS patient care.
- The NCCN Guidelines serve as a vital resource for clinicians managing STS.
- Evidence-based recommendations facilitate standardized and effective treatment of soft tissue sarcomas.
Related Concept Videos
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.3K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.3K
01:19Standards of Care II
722
Nurses bear specific legal responsibilities under several federal statutes, including:
722
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K